As filed with the Securities and Exchange Commission on May 31, 2022
No. 333-259353
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-259353
UNDER
THE SECURITIES ACT OF 1933
Checkmate Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 37-1657129 | |
|
(State or other jurisdiction of incorporation or organization) |
(I.R.S. employer identification no.) | |
|
Nouhad Husseini Managing Director | ||
| 245 Main Street, 2nd Floor | 245 Main Street, 2nd Floor | |
| Cambridge, MA 02142 | Cambridge, MA 02142 | |
| (617) 682-3625 | (617) 682-3625 | |
| (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) | (Name, address, including zip code, and telephone number, including area code, of agent for service) | |
With a copy to:
Andrew R. Brownstein, Esq.
Victor Goldfeld, Esq.
John L. Robinson, Esq.
Wachtell, Lipton, Rosen & Katz
51 West 52nd Street
New York, NY 10019
(212) 403-1000
Approximate date of commencement of proposed sale to the public: Not applicable.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ¨
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ¨
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ¨
If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ¨ | Accelerated filer | ¨ |
| Non-accelerated filer | x | Smaller reporting company | x |
| Emerging growth company | x |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
DEREGISTRATION OF SECURITIES
This Post-Effective Amendment (the “Post-Effective Amendment”) relates to the Registration Statement on Form S-3 (Commission File No. 333-259353), originally filed by Checkmate Pharmaceuticals, Inc., a Delaware corporation (“Checkmate”), with the Securities and Exchange Commission (the “Commission”) on September 7, 2021 (the “Registration Statement”), registering up to $150,000,000 in aggregate principal amount for issuance of the Company’s common stock, preferred stock, debt securities, warrants and/or units, in any combination, together or separately, in one or more offerings in amounts. The Registration Statement became effective on September 15, 2021.
On May 31, 2022, pursuant to that certain Agreement and Plan of Merger, dated as of April 18, 2022 (the “Merger Agreement”), by and among Checkmate, Regeneron Pharmaceuticals, Inc., a New York corporation (“Regeneron”), and Scandinavian Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Regeneron (“Purchaser”), Purchaser merged with and into Checkmate, with Checkmate surviving as a wholly owned subsidiary of Regeneron.
As a result of the transactions contemplated in the Merger Agreement, Checkmate has terminated all offerings of its securities pursuant to the Registration Statement. Checkmate, by filing this Post-Effective Amendment, hereby terminates the effectiveness of the Registration Statement and removes from registration any and all securities registered but unsold under the Registration Statement as of the date hereof. As a result of this deregistration, no securities remain registered for sale pursuant to the Registration Statement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended (the “Securities Act”), the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Greenburgh, State of New York, on this day of May 31, 2022.*
| CHECKMATE PHARMACEUTICALS, INC. | ||
| By: | /s/ Nouhad Husseini | |
| Name: Nouhad Husseini | ||
| Title: Managing Director | ||
* Pursuant to Rule 478 under the Securities Act no other person is required to sign this Post-Effective Amendment.